Theranostics Australia


Private Theranostics Provider in Australia

We strive to develop and provide powerful innovative therapies

Established in May 2015, we are dedicated to continuously developing and utilising targeted molecular diagnostic imaging and therapeutic agents for the diagnosis and treatment of cancers. We have a particular focus on cancers which are difficult to treat or are becoming resistant to conventional therapies. Contact us today to find out more.

Our knowledge of how to treat cancer is the culmination of years of research, education and application of the most innovative developments in the field. Our team of specialists, supported by advanced technologies at our facilities, works tirelessly to offer the most innovative cancer treatments on the market.

For more information, select a cancer type to be directed to a therapy offered by Theranostics Australia.

For modern cancer treatment and a team of specialists who care about your wellbeing, contact us today.

Lutetium-177 Octreotate therapy

Lutetium-177 Octreotate therapy is used to treat neuroendocrine tumours (NETs) that emerge from the endocrine or nervous system such as carcinoid tumours. It aims to reduce the size of the tumour(s) and stop them from multiplying, as well as to ease the associated symptoms. Read More

Lutetium-177 PSMA therapy

Lutetium-177 PSMA therapy is used for people with advanced prostate cancer. It is most often used when the disease has metastasised, and when other therapies are poorly tolerated or have failed. In certain patients, it can produce long-term remission. Read More

Radium-223 therapy

Radium-223 therapy is used for people who have prostate cancer that has spread to the bones. The therapy damages the cancer cells in the bone, leading to the tumours shrinking in size, or even disappearing altogether. It is also used to reduce pain that can be associated with bone cancer. Read More

Iodine-131 therapy

Iodine-131 therapy is a thyroid cancer treatment that uses radiation to treat either thyroid cancer or a hyperactive thyroid (thyrotoxicosis) by targeting the thyroid tissue. Read More

Yttrium-90 SIRT therapy

Yttrium-90 SIRT Therapy, or Selective Internal Radiation Therapy, is a treatment for cancers and tumours located within the liver. The aim of this treatment is to reduce the size of inoperable tumours or decrease the number of lesions in the liver. It may allow for the surgical removal of tumours, once considered inoperable. It may also stabilise the disease and prolong the life of the patient. Read More

Yttrium-90 Radiosynovectomy therapy

Yttrium-90 Radiosynovectomy therapy is a treatment for painful joints caused by arthritis or other types of joint diseases, often providing relief for sufferers. Read More

Theranostics Australia has collaborative ties to


Symposium on Theranostics – Eckert & Ziegler and Imaxeon

Theranostics Australia’s A/Prof Nat Lenzo will be presenting on clinical patient experience for Lutetium-177 PSMA therapy at the Eckert & Ziegler and Imaxeon “Symposium on Theranostics”, following the conclusion of the 4th Theranostics World Congress in Melbourne, VIC.

4th Theranostics World Congress

Today sees the start of the 4th #Theranostics World Congress in#Melbourne. 2016’s theme is “if you can see it, you can treat it”. Find out more about this conference & its importance in the continued treatment of#cancer >>>

Member of the National Imaging Facility (NIF) Industry Advisory Panel

Theranostics Australia’s A/Prof Nat Lenzo has joined the National Imaging Facility (NIF) as a member of their Industry Advisory Panel. NIF is an Australian-wide network of world-class imaging infrastructure that merges cutting-edge imaging technologies with highly specialised expertise from 10 universities and research institutes, along with ANSTO, to develop advanced imaging solutions and drive innovation. The NIF Industry Advisory Panel will provide insight and consultation to NIF to improve strategies for increasing collaboration with national and international commercial parties.